- Home
- DARE vs COEP Comparison
DARE vs COEP Comparison
Compare DARE & COEP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DARE
- COEP
- Stock Information
- Founded
- DARE 2015
- COEP 2017
- Country
- DARE United States
- COEP United States
- Employees
- DARE N/A
- COEP N/A
- Industry
- DARE Biotechnology: Pharmaceutical Preparations
- COEP Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- DARE Health Care
- COEP Health Care
- Exchange
- DARE Nasdaq
- COEP Nasdaq
- Market Cap
- DARE 26.3M
- COEP 27.4M
- IPO Year
- DARE N/A
- COEP N/A
- Fundamental
- Price
- DARE $2.55
- COEP $11.20
- Analyst Decision
- DARE Strong Buy
- COEP
- Analyst Count
- DARE 3
- COEP 0
- Target Price
- DARE $12.50
- COEP N/A
- AVG Volume (30 Days)
- DARE 4.3M
- COEP 39.2K
- Earning Date
- DARE 08-11-2025
- COEP 08-15-2025
- Dividend Yield
- DARE N/A
- COEP N/A
- EPS Growth
- DARE N/A
- COEP N/A
- EPS
- DARE N/A
- COEP N/A
- Revenue
- DARE $25,909.00
- COEP $62,874.00
- Revenue This Year
- DARE $74,787.57
- COEP N/A
- Revenue Next Year
- DARE $141.76
- COEP N/A
- P/E Ratio
- DARE N/A
- COEP N/A
- Revenue Growth
- DARE N/A
- COEP N/A
- 52 Week Low
- DARE $2.11
- COEP $2.31
- 52 Week High
- DARE $9.19
- COEP $13.70
- Technical
- Relative Strength Index (RSI)
- DARE 44.40
- COEP 64.36
- Support Level
- DARE $2.11
- COEP $7.25
- Resistance Level
- DARE $9.19
- COEP $10.00
- Average True Range (ATR)
- DARE 0.60
- COEP 0.52
- MACD
- DARE 0.03
- COEP 0.27
- Stochastic Oscillator
- DARE 5.52
- COEP 93.91
About DARE Dare Bioscience Inc.
Dare Bioscience Inc is a biopharmaceutical company committed to advancing products for women's health. The company identifies, develops, and brings to market a diverse portfolio of differentiated therapies that prioritize women's health and well-being, expand treatment options, and improve outcomes, in the areas of contraception, fertility, and vaginal and sexual health. The company's first product, XACIATO is a single-dose vaginal gel prescription product for the treatment of bacterial vaginosis in females 12 years of age and older. The company's portfolio includes two product candidates in clinical development namely, Ovaprene and Sildenafil Cream. It has one operating segment, women's health.
About COEP Coeptis Therapeutics Holdings Inc.
Coeptis Therapeutics Holdings Inc is a biopharmaceutical company developing cell therapy platforms for patients with cancer. The company's product portfolio consists of multi-antigen CAR T technology licensed from the University of Pittsburgh (SNAP-CAR), a cell therapy technology (CD38-GEAR-NK), and an in vitro diagnostic (CD38-Diagnostic) targeting CD38-related cancers, which the company is developing with VyGen-Bio and medical researchers at the Karolinska Institutet.